Skip to main content
Arjan Diepstra
dr.

As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.

Human alternative Klotho mRNA is a nonsense-mediated mRNA decay target inefficiently spliced in renal disease
Published in: JCI Insight
Access to document 10.1172/jci.insight.94375 document
Klotho is a renal protein involved in phosphate homeostasis, which is down-regulated in renaldisease. It has long been considered an anti-ageing factor. Two Klotho gene transcripts arethought to encode membrane-bound and secreted Klotho. Indeed, soluble Klotho is detectable in bodily fluids, but the relative contributions of Klotho secretion and of membrane-bound Klotho shedding are unknown. Recent advances in RNA surveillance reveal that premature termination codons, as present in alternative Klotho mRNA (for secreted Klotho), prime mRNAs for degradation by nonsense-mediated mRNA decay (NMD). Disruption of NMD led to...
Rik Mencke, Geert Harms, Jill Moser, Matijs van Meurs, Arjan Diepstra, Henri G.D. Leuvenink, Jan-Luuk Hillebrands
HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
Published in: OncoImmunology
Access to document 10.1080/2162402X.2017.1295202 document
Antigen presentation by tumor cells in the context of Human Leukocyte Antigen (HLA) is generally considered to be a prerequisite for effective immune checkpoint inhibitor therapy. We evaluated cell surface HLA class I, HLA class II and cytoplasmic HLA-DM staining by immunohistochemistry (IHC) in 389 classical Hodgkin lymphomas (cHL), 22 nodular lymphocyte predominant Hodgkin lymphomas (NLPHL), 137 diffuse large B-cell lymphomas (DLBCL), 39 primary central nervous system lymphomas (PCNSL) and 19 testicular lymphomas. We describe a novel mechanism of immune escape in which loss of HLA-DM expression results...
Marcel Nijland, Rianne N. Veenstra, Lydia Visser, Chuanhui Xu, Kushi Kushekhar, Gustaaf W. van Imhoff, Philip M. Kluin, Anke van den Berg, Arjan Diepstra
Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma
Published in: International Journal of Molecular Sciences
Access to document 10.3390/ijms17122127 document
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is characterized by a low percentage of neoplastic lymphocyte predominant (LP) cells in a background of lymphocytes. The goal of this study is to characterize the microenvironment in NLPHL. Ten NLPHL cases and seven reactive lymph nodes (RLN) were analyzed by flow cytometry for the main immune cells and multiple specific subpopulations. To discriminate between cells in or outside the tumor cell area, we used CD26. We observed significantly lower levels of CD20+ B-cells and CD56+ NK cells and higher levels of...
Lydia Visser, Rui Wu, Bea Rutgers, Arjan Diepstra, Anke van den Berg
A Novel Prognostic Model Based on Tumor Microenvironment Biology in Relapse Biopsies Predicts Post-Autologous Stem Cell Transplantation Outcomes in Classical Hodgkin Lymphoma
Fong Chun Chan, Anja Mottok, Alina S. Gerrie, Maryse M. Power, Kerry J. Savage, Marcel Nijland, Arjan Diepstra, Anke Van den Berg, Joseph M. Connors, Randy D. Gascoyne, Sohrab P. Shah, David W. Scott, Christian Steidl
Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC
Published in: British Journal of Haematology
Access to document 10.1111/bjh.14317
Soluble Galectin-1 (sGal-1, also termed LGALS1), soluble CD163 (sCD163) and soluble CD30 (sCD30) have been reported to be elevated in plasma or serum of patients with classical Hodgkin lymphoma (cHL). We aimed to determine the clinical utility of these biomarkers for evaluation of treatment response compared to thymus and activation regulated chemokine (TARC, also termed CCL17). Plasma or serum samples were prospectively collected among 103 newly diagnosed cHL patients before and after treatment. Levels of sGal-1, sCD163, sCD30 and TARC were correlated with disease characteristics and clinical treatment...
Wouter J. Plattel, Zainab N. D. Alsada, Gustaaf W. van Imhoff, Arjan Diepstra, Anke van den Berg, Lydia Visser